ADSL Antibody

Adenylosuccinate lyase (ASL), also known as adenylosuccinase, is an enzyme that plays a crucial role in the purine nucleotide cycle. This enzyme is encoded by the ADSL gene in humans and is responsible for converting adenylosuccinate to adenosine monophosphate (AMP) and fumarate . The enzyme catalyzes two key reactions in the de novo purine biosynthetic pathway, which are essential for the synthesis of AMP .

Adenylosuccinate lyase is a homotetrameric enzyme, meaning it consists of four identical subunits. Each subunit has three distinct domains that contribute to the enzyme’s overall structure and function . The enzyme’s primary function is to catalyze the cleavage of adenylosuccinate into AMP and fumarate, as well as the cleavage of SAICAR (succinylaminoimidazolecarboxamide ribose-5’-phosphate) into AICAR (aminoimidazolecarboxamide ribose-5’-phosphate) and fumarate .

The activity of adenylosuccinate lyase is vital for the proper functioning of the purine nucleotide cycle, which is essential for the synthesis of nucleotides and nucleic acids. This cycle is crucial for various cellular processes, including DNA and RNA synthesis, energy metabolism, and signal transduction . Deficiencies in adenylosuccinate lyase activity can lead to severe metabolic disorders, such as adenylosuccinate lyase deficiency (ADSLD), which is characterized by a wide range of clinical symptoms, including developmental delay, seizures, and autistic features .

Mouse anti-human adenylosuccinate lyase antibodies are used in various research applications to study the enzyme’s function, expression, and role in different biological processes. These antibodies are generated by immunizing mice with human adenylosuccinate lyase protein, leading to the production of specific antibodies that can recognize and bind to the human enzyme. These antibodies are valuable tools for investigating the enzyme’s role in health and disease, as well as for developing potential therapeutic strategies .

Research has shown that adenylosuccinate lyase is involved in various pathological conditions, including cancer. For instance, elevated expression of the ADSL gene has been observed in prostate cancer tissues, and its increased expression is associated with poor prognosis . Inhibiting the expression of ADSL in prostate cancer cell lines has been shown to reduce cell proliferation and migration, indicating its potential as a therapeutic target .